Cohort study on the treatment of BRAF V600E mutant metastatic colorectal cancer with integrated Chinese and western medicine

doi:10.5306/wjco.v16.i1.93670

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (493)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

HTML

232

Figures (1-3)

Tables (1-2)

Sum=358

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=116

Publishing Process of This Article

Item

Count

Browse

Download

Sum=9

Jan 24, 2025 (publication date) through Nov 21, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Clin Oncol. Jan 24, 2025; 16(1): 93670
Published online Jan 24, 2025. doi: 10.5306/wjco.v16.i1.93670

Open in New Tab Full Size Figure Download Figure

Figure 1 Screening flowchart. mCRC: Metastatic colorectal cancer; OS: Overall survival.

Open in New Tab Full Size Figure Download Figure

Figure 2 Comparison of overall survival between two cohorts. HR: Hazard ratio; OS: Overall survival.

Open in New Tab Full Size Figure Download Figure

Figure 3 Comparison of overall survival in subgroup. A: Overall survival (OS) of right-side colon; B: OS of liver metastases; C: OS of targeted therapy; D: OS of chemotherapy; E: OS of 1^st line therapy. HR: Hazard ratio; OS: Overall survival.

Citation: Bian JY, Feng YF, He WT, Zhang T. Cohort study on the treatment of BRAF V600E mutant metastatic colorectal cancer with integrated Chinese and western medicine. World J Clin Oncol 2025; 16(1): 93670
URL: https://www.wjgnet.com/2218-4333/full/v16/i1/93670.htm
DOI: https://dx.doi.org/10.5306/wjco.v16.i1.93670